SEVERAL INVESTIGATORS have reported the presence of antibodies to the shared (interspecies or "gs-3") determinant(s) of the major, 30,000 mol wt structural protein of mammalian type-C RNA tumor viruses in the sera (1) or renal eluates (2) of cancer patients. If confirmed, such findings would constitute strong indirect evidence for the existence of a human type-C virus.
The methodology in the above studies (immunofluorescence and complement-fixation inhibition), however, makes it difficult to interpret the specificity of the results. This is particularly so with the complementfixation inhibition tests in which viruses disrupted by Tween-ether were used as control antigens and in the immunofluorescence studies in which virus-shedding tissue cultures were the antigens. Despite absorptions, the reactions observed could well be due to antibodies to cellular or other uncharacterized antigens.
One recent report (1) of gs-3 antibodies in the sera of 50-80% of cancer patients, but in only 0.2-10% of normal controls, by the complement-fixation inhibition test, prompted us to search for cross-reacting (gs-3) antibodies in the sera of adult and juvenile cancer patients and controls, of children with tumors, of young patients with connective tissue disorders including systemic lupus erythematosis, and of laboratory workers involved in either the mass production of, or research on, type-C RNA tumor viruses.
We studied these sera using radioimmunoassay under conditions assuring maximal antibody binding; this technique has the advantages of both greater sensitivity and specificity. We used as our probe highly purified, isoelectric-focused murine leukemia virus (MuL V) group-specific (gs) antigen, a 30,000 mol wt protein carrying the gs-3 mammalian determinant(s) .
MATERIALS AND METHODS
A lymphoid cell line shedding NZB MuL V (strain SCRF 60 A ) (3) was obtained from Fred Jensen (Scripps Research Institute, La Jolla, Calif.). The major structural protein (p30) was purified from banded virus by isoelectric focusing in ampholytes as previously reported (4) . The gs antigen was separated from ampholytes by Bio-Gel P-100 chromatography in 0.3M ammonium acetate buffer, pH 6.9, and the fraction containing peak complement-fixing activity was checked for purity on polyacrylamide gel electrophoresis by the method of Weber and Osborn (5) . Fractions containing a single, visible protein band were pooled, lyophilized, and redissolved in 0.15M sodium phosphate buffer, pH 7.5, at = I p.g/ p.l. Purified gs antigen was iodinated with 1251 (Amersham) by the method of Greenwood et al. (6) . Free iodine and protein-bound iodine were separated by Sephadex G-100 chromatography. Protein-containing fractions were precipitated with trichloroacetic acid (TCA) by the addition of 10 p.l radioactive fraction, 1.0 ml 10% normal rabbit serum carrier, and 1.0 ml 30% TCA. After being well mixed, reaction tubes were incubated for 30-60 minutes at 4° C followed by centrifugation at 6000 rpm in a Beckman J-21 centrifuge with a JA-14 rotor having inserts (Beckman) for 12X75-mm glass tubes.
TCA precipitability was calculated as the percentage of total counts found in unwashed precipitates. Fractions >97% TCA-precipitable were pooled and diluted to about 5000 counts per minute (cpm)/ 100 p.l in O.OIM Tris-HCl, pH 7.2, containing 0.85% NaCl and 0.5% bovine serum albumin (Pentex) for radioimmunoassays.
Labeled protein was checked by polyacrylamide gel electrophoresis for minor contaminants not visible on stained gels. The complement-fixation procedure was previously reported (4).
Sera.-A goat antiserum (IS-8) to feline leukemia virus disrupted by Tween-ether was obtained from Dr. Roger Wilsnack (Huntingdon Research Center, Baltimore, Md.). It has high-titered homologous and cross-reacting antibodies to RNA tumor virus gs antigens. Sera from cancer patients with histologically confirmed metastatic disease were available from a previous study (7) . Sera from children, most of whom had malignant neoplasms, were supplied by Dr Robert McAllister (Childrens Hospital of Los Angeles, Los Angeles, Calif.). Sera from juvenile patients with connective tissue disorders, including scleroder rna, systemic lupus erythematosis, dermatomyositis, and rheumatoid arthritis, were provided by Dr. Virgil Hanson (Childrens Hospital of Los Angeles). Sera were collected from laboratory technicians responsible for mass production of RNA tumor virus from virusshedding tissue cultures and from those involved in the production of various virus reagents. The length of employment and job description are summarized in "Results" (see table 4 ). The longest exposure to those viruses was 11 years; the shortest was 37 weeks. The greatest potential exposure to these viruses was in 2 technicians who grew viruses in mass culture and in 4 technicians who prepared banded virus from virusinfected tissue-culture fluids. Three other employees produced purified antigens from banded virus materials. The remainder worked on studies of various tumor viruses or with subviral components such as the gs antigens.
Radioimmunoassays.-Radioimmunoassays were as previously reported (7) except that 42.5% ammonium sulfate (8-10) was used to separate antibody-free from antibody-bound activity. Reactions were performed in 3 ml polycarbonate test tubes presoaked with 10% normal rabbit serum. Each reaction tube contained 300 }.II consisting of 100 }.II of each of the following: labeled NZB gs antigen, =5000 cpm; O.OlM TrisHCl; 0.85% NaCl buffer, pH 7.2; and either test or control serum at the indicated dilutions. Reaction mixtures were incubated for 2 hours at 37° C and then for 2~ days at 4° C. An equal volume of 85% saturated ammonium sulfate was then added, mixed well, and allowed to stand 2-3 hours at 4° C. Free antigen and antibody-bound antigen were then separated by centrifugation for 15 minutes at 12,000 rpm in a Beckman .1-21 centrifuge having a JA-14 rotor equipped with special plastic adaptors. Supernatants were decanted, residual fluid was wiped from the mouth of the tube with a cotton swab, and the precipitates were determined in a Nuclear Chicago 1185 Autogamma counter with a calculated efficiency of 75% for a simulated 125 1 standard (Nuclear Chicago). Initial dilutions in a set were performed manually; subsequent dilutions and reagent additions were done with a Micromedic Automatic Pipetting Station. Ammonium sulfate was added with an Oxford pipettor. Tests were performed in 2 separate runs about 1 week apart. Each run had 2 complete titrations of IS-8 located physically at the beginning and end. All antibody dilutions within each run were identical; the initial 1: 500 dilutions were prepared from different vials of low-dilution IS-8.
In addition to the tube method in which ammonium sulfate was used to separate free and antibody-bound antigen, a double antibody procedure in which sucrose density gradients were used was employed. This allowed the use of undiluted sera and avoided technical limitations inherent in the ammonium sulfate technique at serum dilutions < 1: 25. At such dilutions, trapping of 125I_gs antigen is considerable in the presence of normal sera, regardless of species of origin. With minimal sacrifice in sensitivity, the gradient procedure gave negative results with normal sera (see "Results").
This test was performed on 20 samples of childhood leukemic sera and normal control sera as follows: 100 }.II each of buffer, labeled antigen (= 7000 cpm), and appropriate normal or test serum were incubated for 3 hours at 37° C and then for 18 hours at 4° C. Antispecies globulin (Cappel Laboratories), sufficient to precipitate all globulin (about 0.5 ml), was then added and reaction tubes were incubated at 37° C for 3 hours and at 4° C for 2 hours. Reaction mixtures were gently layered on top of 5.0 ml 5-20% sucrose density gradients, and incubation tubes washed with 100 ",1 0.01 Tris-Hel and 0.15M NaCl buffer. Tubes were centrifuged for 17 hours at 35,000 rpm with a Beckman 40.3 rotor in a Beckman LS-350 ultracentrifuge. Twenty-drop fractions were collected by bottom puncture, and the radioactivity in each fraction, precipitates, and incubation tubes was determined. Appropriate controls included the known positive serum IS-8, normal human serum, and normal human serum containing trace-labeled normal human 'Y-globulin. Results were calculated from the percentage of total recovered counts found in the precipitate and in each fraction.
Data processing.-Programs were written for a Wang 600~6 desk-top computer equipped with a Wang 602 Plotting Output Writer and a Wang 603 Paper Tape Editor to read the teletype output of the gamma counter, calculate the statistics (11) To facilitate comparison of diseased and normal human sera, the formula was modified as follows: % precipitated = 100 :=:, where b = counts nonspecifically bound when 100 }.II labeled antigen and 200 }.II buffer were incubated under the above conditions and precipitated by ammonium sulfate. figure 1 shows the electrophoretic pattern of the labeled gs antigen. The labeled protein migrated as a single band of =31,000 mol wt, which contained about 95% of the recovered activity.
RESULTS

Text-
Text- figure 2 shows the immunoreactivity of this antigen with high-titered goat anti-feline leukemia virus (IS-8). About 90% of input counts were bound in antibody excess. The 50% binding titers, calculated by the least-squares method through the linear central portion of the curves, were 82,000 and 90,000 (86,000±6.6%) on ~he first set of experiments and 39,500 and 39,900 (39, 700±0. 7%) on the second set. The 10% intercepts were 493,000 and 453,000 (473,000±6%) for the first s.et and 178,000 and 212,000 (195,000±12%) for the second set. Table 1 shows the diagnoses of cancer in the adult patients screened. Cancer sera did not differ from control sera. No serum precipitated >9% of input counts; the dilutional effects characteristic of an antigen-antibody reaction were not noted in any serum tested. Typical negative patient and control curves are shown in text-figure 3. Table 2 shows the diagnoses of neoplasms in children. Table 3 shows the number and diagnoses of
FRACTION NUMBER
TEXT-FIGURE I.-Labeled gs protein (100,000 cpm) was heatdissociated for 60 seconds in a boiling water bath and applied to a lO-cm 7.5% acrylamide gel. After 4% hours' electrophoresis at 8 milliamperes/gel, the gel was placed in acetic acid-Coomassie blue. Gels were electrolytically destained and the location of marker proteins was noted. After being cut with a mechanical knife into I-mm sections, gels were counted and plotted with a Wang computer. Background counts were not corrected. 
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L~O ANTISERUM DILUTION TEXT-FIGURE 2.-A total of 100 "I (5000 cpm) MuLV gs antigen, 100 "I buffer, and 100 ~ of serial twofold dilutions of IS-8 was incubated for 2 hours at 37° C and then for 2% days at 4° C. Then 300 "I ammonium sulfate was added, mixed well, and further incubated for I hour at 4° C. After centrifugation for 15 minutes at 12',000 rpm, supernatants were discarded and precipitates counted. The percentage of counts bound were plotted after subtraction of the nonspecific precipitation of a I: 100 dilution of normal goat serum (Cappell Laboratories connective tissue disorders in juvenile patients. No antibody activity was noted in these sera. Table 4 lists the employees, most of whom worked closely with RNA tumor viruses. Sera from all workers lacked antibodies to the murine gs antigen.
Systemic sclerosis _____ ---------------------51 Systemic lupus erythematosis_ --------------
The above results were obtained by the ammonium sulfate method to separate antigen-antibody complexes from free antigen. With the current labeled antigen preparations, high concentrations of 'Yglobulin (serum dilutions < I: 10), regardless of species of origin, gave considerable precipitation ( = 50% binding). To distinguish this activity from true antibody precipitation, mixtures of labeled antigen and test serum were precipitated with antispecies antibody and assayed by centrifugation in sucrose gradients. Free antigen was found in the upper part of the gradient; antibody-bound antigen was found in the precipitate and lower 1-2 fractions. Antigen did not bind to the gradient tube; thus each assay permitted quantitative recovery of input antigen. In addition, experiments with trace-labeled 'Y-globulin established that the antispecies antibodies precipitated 100% of the test serum globulin. This procedure is obviously more tedious than the tube method but effectively eliminates nonspecific binding with minimal sacrifice in sensitivity. It also allows the use of undiluted test serum. In addition to samples of normal human, guinea pig, and goat sera, 20 samples of human leukemic sera were assayed by this procedure. These were from 8 patients with acute lymphocytic leukemia. In contrast to results with a known positive antiserum (50% endpoint-I: 10,000), none of these serum samples bound >7% of the input antigen and all sera averaged =4% binding. Buffer controls (no serum added) gave a similar low degree of binding; thus these minimal values are not based on specific interactions.
DISCUSSION
The Farr technique, based on the precipitation of antibody globulin at ammonium sulfate concentrations near half saturation, has long been used as a measure of total antigen-binding capacity. Soluble antigen-antibody complexes and non-complementfixing or poorly complement-fixing and nonprecipitating antibodies are easily demonstrated by this method. We and others (9) have determined that ammonium sulfate at final concentrations of 41.5-42.5% optimally precipitates MuL V gs antigenantibody complexes while retaining an acceptable background on nonspecific precipitation of label in the absence of serum.
Bonafide antigen-antibody reactions result in a sigmoidal dose-response curve when the percentage of counts specifically precipitated is plotted against the logarithm of the reciprocal of antiserum dilution. In our experience with several hundred immune serum titrations, this curve has a linear portion, usually covering the range of about 10-90% bound. Some antisera with partially cross-reacting antibodies show diminished maximal binding in antibody excess. In such instances, however, there is still a range where Virus assays, antigen purification, animal immunization.
Continuous flow centrifugation and collection of fractions from large volumes of viral fluids.
In vitro assays of virus infectivity and cell transformation.
Purification and assay of viral subunits, routine tests of viral pellets and tissue culture cell concentrates.
Purification and molecular hybridization with viral nucleic acids, in vitro assays of virus activity.
General cleaning, autoclaving of flasks and large containers used in virus processing. the dose-response curve is linear. Nothing resembling this was seen with any human sera. In our experience, radioimmunoassays are 100-to 1000-fold more sensitive in detection of antibody than conventional complement-fixation tests. In addition, radioimmunoassay detects antibody in sera which fix complement poorly. The immune serum, IS-8, has a complement-fixing titer of <20, yet bound heterologous gs antigen at dilutions of 220,000-470,000 in radioimmunoassay.
Cross-reacting (gs-3) antibodies precipitating highly purified MuL V gs antigen were not detected in the sera of 25 adult patients or controls, of 52 children with cancer, or of 20 patients with connective tissue disorders including systemic lupus erythematosis, a condition associated with the formation of autoantibodies to a variety of normal cell constituents. Sera of employees working intimately with these viruses and using approved safety precautions were also free of demonstrable antibody activity.
The ammonium sulfate tube technique as described herein has limitations which prevented its unambiguous use at serum dilutions < 1: 25. This was based on nonspecific trapping of labeled antigen, since normal sera of several species give the same result. Even if one considers this factor, the procedure is > 100-fold more sensitive for complement-fixing, reactive, homologous sera and 1000-10,000 fold more sensitive for heterologous sera containing gs-3 antibodies (e.g., IS-8). Undiluted sera could however be used in the gradient procedure, since nonspecific trapping is evidently circumvented. Under these conditions 100% of trace-labeled normal 'Y-globulin was precipitated by antispecies antibody while, at the same time, such sera bound < 5% of labeled MuL V gs. Twenty samples ofleukemic sera and some samples of normal control sera so assayed were completely negative, whereas the control anti-gs-3 serum bound 50% of the labeled antigen at a dilution of 1 : 10,000.
Thus, contrary to what others have found in initial experiments with uncharacterized antigens, using highly purified antigen and a sensitive radioimmunoassay system, under the conditions stated, we failed to find cross-reacting (gs-3) antibodies to MuLV gs determinant(s) in a variety of normal and diseased hum~n sera. These results have no implications regardmg the presence of a human type-C virus. Our results do not deny the potential importance of the ~es~lts described by O.lsen and y ohn (J); they do mdicate that the reactIOns descnbed were not with gs-3 determinants associated with the 30,000 mol wt viral protein.
